Fresenius Medical Care AG
FME: XETR (DEU)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€84.00 | Ywkby | Ynpp |
Fresenius Medical Care Earnings: Underlying Growth and Margin Improvement Boost 2023 Outlook
In a positive development, narrow-moat Fresenius Medical Care turned in solid third-quarter results and increased its guidance for the full year. We do not anticipate changing our fair value estimate on the company. However, we recognize continued improvement in its profit prospect could act as a catalyst for its undervalued shares, assuming potential obesity drug effects do not derail the progress.